The US FDA has approved sunvozertinib for adult patients with locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations. Clinical evidence In a clinical trial involving 85 patients, sunvozertinib demonstrated an overall response rate of 46% and a median duration of response of 11 months.
Dosage and administration Available in tablet form Dosage: 200 mg orally once daily taken with food Contraindications – None Warnings and precautions Interstitial lung disease /pneumonitis Gastrointestinal adverse reactions Dermatologic adverse reactions Ocular toxicity Embryo-fetal toxicity Adverse reactions Diarrhea, rash, decreased appetite, stomatitis, fatigue, nausea, paronychia, vomiting, constipation, musculoskeletal pain, pruritus, dry skin, urinary tract infection, abdominal pain, decreased weight Decreased lymphocytes,…
